+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

STD Testing: Global Strategic Business Report

  • PDF Icon

    Report

  • 197 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5141566

Global STD Testing Market to Reach $144.8 Billion by 2030

The global market for STD Testing estimated at US$97.3 Billion in the year 2022, is projected to reach a revised size of US$144.8 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2022-2030. Chlamydia, one of the segments analyzed in the report, is projected to record 4.9% CAGR and reach US$40.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Herpes Simplex Virus segment is readjusted to a revised 5.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $26.3 Billion, While China is Forecast to Grow at 8.1% CAGR

The STD Testing market in the U.S. is estimated at US$26.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$31.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.8% and 4.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Select Competitors (Total 47 Featured) -

  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • STD Testing - Global Key Competitors Percentage Market Share in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World STD Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 3: World Historic Review for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 4: World 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 6: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 7: World 16-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 9: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 10: World 16-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 12: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 13: World 16-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for Human Papillomavirus (HPV) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 22: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 24: World Historic Review for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 25: World 16-Year Perspective for Laboratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 27: World Historic Review for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 28: World 16-Year Perspective for Point-of-Care (POC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: USA Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: USA 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: USA Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: USA 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • CANADA
  • Table 35: Canada Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: Canada Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: Canada 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 38: Canada Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Canada Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Canada 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • JAPAN
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 41: Japan Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Japan Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Japan 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 44: Japan Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Japan Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Japan 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • CHINA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 47: China Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: China Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: China 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 50: China Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: China Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: China 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • EUROPE
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 53: Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 56: Europe Recent Past, Current & Future Analysis for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 57: Europe Historic Review for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: Europe 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 59: Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • FRANCE
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 62: France Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: France Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: France 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 65: France Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 66: France Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: France 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • GERMANY
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 68: Germany Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Germany Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: Germany 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 71: Germany Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Germany Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: Germany 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • ITALY
  • Table 74: Italy Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Italy Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Italy 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 77: Italy Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: Italy Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: Italy 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 80: UK Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: UK Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: UK 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 83: UK Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: UK Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: UK 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • SPAIN
  • Table 86: Spain Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Spain Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Spain 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 89: Spain Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Spain Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Spain 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • RUSSIA
  • Table 92: Russia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Russia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Russia 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 95: Russia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Russia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Russia 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Rest of Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Rest of Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 101: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: Rest of Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 103: Rest of Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2023 & 2030
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 108: Asia-Pacific Historic Review for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 109: Asia-Pacific 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • Table 110: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 111: Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 112: Asia-Pacific 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
  • AUSTRALIA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.

Table Information